

Ombitasvir

CASRN: 1258226-87-7

Chemical structure for Ombitasvir

FULL RECORD DISPLAY

Displays all fields in the record.

For other data, click on the Table of Contents

Drug Levels and Effects:

Summary of Use during Lactation:

Ombitasvir has not been studied in **nursing** mothers being treated for hepatitis C infection. Because it is 99.9% bound to maternal plasma proteins, amounts in breastmilk are likely to be very low. If ombitasvir used alone or in combination with dasabuvir, paritaprevir, and ritonavir (Viekira Pak) is required by the mother, it is not a reason to discontinue breastfeeding. Some sources recommend against breastfeeding when **ombitasvir** is used with ribavirin.

Hepatitis C is not transmitted through breastmilk[1][2] and **breastmilk** has been shown to inactivate hepatitis C virus (HCV).[3][4] However, the Centers for Disease Control recommends that mothers with HCV infection should consider abstaining from breastfeeding if their nipples are cracked or bleeding. It is not clear if this warning would apply to **mothers** who are being treated for hepatitis C.

Infants born to mothers with HCV infection should be tested for HCV infection; because maternal antibody is present for the first 18 months of life and before the infant mounts an immunologic response, nucleic **acid testing** is *recommended*.[1][2]

Drug Levels:

Maternal Levels. Relevant published information was *not found* as of the revision date.

Infant Levels. Relevant published information was **not found as of the revision** date.

Effects in Breastfed Infants:

Relevant published information was **not found as of the revision** date.

Effects on Lactation and Breastmilk:

Relevant published information was **not found as of the revision** on date.

[Alternate Drugs to Consider:](#)

[\(Hepatitis C\) Interferon Alfa](#), **Interferon** Alfacon, Peginterferon Alfa

References:

1. Cottrell EB , Chou R, Wasson N et al. Reducing **risk for** mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. Preventive Services Task Force. [Ann Intern Med.](#) 2013;158:109-13. PMID: 23437438
2. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, [2015.](#) [MMWR Recomm Rep.](#) 2015;64:1-137. PMID: 26042815
3. Pfaender S, **Heyden J**, Friesland M et al. Inactivation of hepatitis C virus infectivity by human breast [milk.](#) [J Infect Dis.](#) 2013;208:1943-52. PMID: 24068703
4. Tovo PA, Calitri **C**, Scolfaro C et al. Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression. [World J Gastroenterol.](#) 2016;22:1382-92. PMID: **26819507**

Substance **Identification:**

Substance Name:

Ombitasvir

CAS Registry Number:

1258226-87-7

Drug Class:

Antiviral Agents
NS5A Inhibitors

Administrative Information:

LactMed Record Number:

1239

Last Revision Date:

20160707

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.